The Swiss major has got off to a strong start in 2019 with Cosentyx and Entresto sales soaring and Mayzent – and possibly very soon Zolgensma – getting US approvals.
Novartis AG CEO Vas Narasimhan has said that US approval of Zolgensma for spinal muscular atrophy remains on track for May following patient deaths that he believes have led to "misleading or mis-characterized headlines" concerning the safety of the closely watched gene therapy.
Narasimhan was speaking to journalists early this morning (24 April) on a call about Novartis's first quarter 2019 financials and...
Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.
Pfizer showed how to come out on top with investors during earnings season. Post strong sales growth – and avoid mentioning tariffs, most favored nation pricing or Medicare modernization impacts.
The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.
Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.
The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.
